3D Medicines, Inc. (1244) Stock Statistics & Valuation Metrics

3D Medicines, Inc. has a market cap or net worth of HK$1.06B. The enterprise value is HK$714.73M.

3D Medicines, Inc. has 258,177,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

3D Medicines, Inc.’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -13.11%.

The current PE Ratio of 3D Medicines, Inc. is -3.80. 3D Medicines, Inc.’s PEG ratio is -0.11.

In the last 12 months, 3D Medicines, Inc. had revenue of 445.65M and earned -182.66M in profits. Earnings per share was -0.75.

In the last 12 months, operating cash flow was -179.67M and capital expenditures -45.93M, giving a free cash flow of -225.60M billion.

3D Medicines, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

3D Medicines, Inc. upcoming earnings date is Aug 22, 2025, TBA (Not Confirmed).

3D Medicines, Inc. as a current ratio of 2.02, with Debt / Equity ratio of 30.27%

In the past 12 months, 3D Medicines, Inc. has paid 0.00 in taxes.

3D Medicines, Inc. EV to EBITDA ratio is -2.15, with an EV/FCF ratio of 0.00.

3D Medicines, Inc. has HK$840.98M in cash and marketable securities with ¥237.62M in debt, giving a net cash position of -HK$603.36M billion.

Gross margin is 83.42%, with operating margin of -27.70%, and net profit margin of -40.99%.

The average price target for 3D Medicines, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―